<DOC>
	<DOC>NCT01840345</DOC>
	<brief_summary>This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adjunct to opioid treatment in chronic neuropathic pain.</brief_summary>
	<brief_title>The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain</brief_title>
	<detailed_description>This is an open-label study to evaluate the safety and efficacy of N-acetyl-L-cysteine in patients with Chronic neuropathic pain.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>1865 years old noncancer neuropathic pain stable dose of opioids for pain using breakthrough pain meds still with persistent pain per VAS pregnant or nursing serious medical or psychiatric illness (including uncontrolled hypertension) active stomach ulcer, history or seizures or asthma breakthrough pain meds other than opioids using illicit drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>uncontrolled</keyword>
	<keyword>neuropathic pain</keyword>
</DOC>